About Us

2007
In 2007，Clover was founded as a research laboratory

2016
In Jul 2016，Clover executes agreement to establish and build 35,000 sqm commercial-scale cGMP biomanufacturing facility in Changxing, China and secures full-financing for the project (>RMB 350 million / >US$ 55 million)

2017
In Dec 2017，Clover completes Series A financing (RMB 62.8 million / US$ 9.5 million)

2018
In Jun 2018，First patient dosed with a product utilizing Trimer-Tag© technology (Phase 1 study of SCB-313 for treatment of cancer patients with malignant ascites)

2019
In Nov 2019，Clover completes Series B financing (RMB 304 million / US$ 43 million)

2020
In Jan 2020，Clover initiates development of COVID-19 vaccine candidate utilizing Trimer-Tag© technology

2020
In Feb-Mar 2020，Clover announces cross-border research collaborations with GSK and Dynavax utilizing their respective adjuvants for the development of COVID-19 vaccines

2020
In Apr 2020，Funding and collaboration with CEPI announced for Clover’s COVID-19 vaccine

2020
In Jun 2020，Clover completes Series B-2 financing (US$ 24 million / RMB 172 million) from Hillhouse Capital

2020
In Jun 2020，First participant dosed with Clover’s COVID-19 vaccine in Phase 1 clinical study

2020
In Jul 2020，CEPI expands partnership with Clover to rapidly advance development and manufacture of COVID-19 vaccine candidate with an additional USD $66 million investment

2020
In Nov 2020，CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure (up to $328 million in grant funding)

2020
In Dec 2020，Clover announces positive Phase 1 data for its adjuvanted S-Trimer COVID-19 vaccine candidates

2021
In Feb 2021，Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing